bb

The pharma industry is seeing a slowdown in sales in developed countries, so drug makers are turning to emerging markets for growth. Despite challenges, the Indian pharmaceutical market is expected to reach $130 billion by 2030. In 2023, there will be a focus on quality manufacturing, affordability, and innovation. The industry needs to address low R&D spending, skill scarcity, intellectual property, regulations, and export contractions. Improved tracking systems and pricing technology are also important. The government previously implemented a traceability system, but now pharma companies need to strengthen their self-monitoring. trends dominating the pharma industry, a 2023 outlook with a flattening of the growth in pharma sales in developed countries, drug makers are increasingly looking to emerging markets for new sources of growth and revenue. Over the past 10 years, the pharma industry has witnessed greater collaboration, adapted quickly, and adapted innovative approaches to deliver high-quality medicines continuously during the pandemic and beyond. The industry has shown unwavering commitment to support the country's healthcare needs as well as enhance its footprint across the world, according to recent EYFICC analysis, with rising concerns of offering new breakthroughs to patients. The Indian pharmaceutical market is expected to reach $130 billion in value by the end of 2030. A bright future stands ahead for India's pharmaceutical businesses in 2023, with a greater emphasis on quality manufacturing medicines, affordability, and the use of innovation and technology. However, to combat certain challenges like low R&D spending, scarcity of skill level, intellectual property, regulations and rights, and potential export contractions, a high level of agility and readiness is required. Manufacturing are some of the key trends that the industry is likely to experience in the coming years. Proactive quality management system. The medicines manufacturing and distribution supply chain is a long and complex one, but in the coming years, the Indian pharmaceutical industry should look more closely at advanced tracking system and introduce better pricing related technology. This is nothing new for Indian pharmaceutical manufacturers and exporters. The government previously had implemented a comprehensive traceability system known as drug authentication and implemented a comprehensive traceability system known as drug authentication and verification application, DAVA, for both export and domestic markets in 2015. The program provided consumers and regulatory authorities with an easier way to prove drug authenticity and safeguard India's brand image in international markets. However, now the pharma companies will progressively focus on strengthening their self-monitoring system, recognizing their moral needs to do more. Thank you.